These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 29325227)

  • 1. Soluble ST2 in end-stage heart failure, before and after support with a left ventricular assist device.
    Tseng CCS; Huibers MMH; Gaykema LH; Siera-de Koning E; Ramjankhan FZ; Maisel AS; de Jonge N
    Eur J Clin Invest; 2018 Mar; 48(3):. PubMed ID: 29325227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Interleukin-33/ST2 Pathway Is Expressed in the Failing Human Heart and Associated with Pro-fibrotic Remodeling of the Myocardium.
    Tseng CCS; Huibers MMH; van Kuik J; de Weger RA; Vink A; de Jonge N
    J Cardiovasc Transl Res; 2018 Feb; 11(1):15-21. PubMed ID: 29285671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-33/ST2 pathway and classical cytokines in end-stage heart failure patients submitted to left ventricular assist device support: a paradoxic role for inflammatory mediators?
    Caselli C; D'Amico A; Ragusa R; Caruso R; Prescimone T; Cabiati M; Nonini S; Marraccini P; Del Ry S; Trivella MG; Parodi O; Giannessi D
    Mediators Inflamm; 2013; 2013():498703. PubMed ID: 24385685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamics and prognostic role of galectin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation.
    Coromilas E; Que-Xu EC; Moore D; Kato TS; Wu C; Ji R; Givens R; Jorde UP; Takayama H; Naka Y; George I; Mancini D; Schulze PC
    BMC Cardiovasc Disord; 2016 Jun; 16():138. PubMed ID: 27301475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myocardial fibrosis and pro-fibrotic markers in end-stage heart failure patients during continuous-flow left ventricular assist device support.
    Lok SI; Nous FM; van Kuik J; van der Weide P; Winkens B; Kemperman H; Huisman A; Lahpor JR; de Weger RA; de Jonge N
    Eur J Cardiothorac Surg; 2015 Sep; 48(3):407-15. PubMed ID: 25609773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ST2 elevation in heart failure, predictive of a high early mortality.
    Dalal JJ; Digrajkar A; Das B; Bansal M; Toomu A; Maisel AS
    Indian Heart J; 2018; 70(6):822-827. PubMed ID: 30580851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of left ventricular assist device support on biomarkers of cardiovascular stress, fibrosis, fluid homeostasis, inflammation, and renal injury.
    Ahmad T; Wang T; O'Brien EC; Samsky MD; Pura JA; Lokhnygina Y; Rogers JG; Hernandez AF; Craig D; Bowles DE; Milano CA; Shah SH; Januzzi JL; Felker GM; Patel CB
    JACC Heart Fail; 2015 Jan; 3(1):30-39. PubMed ID: 25447345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteopontin: a potential biomarker for heart failure and reverse remodeling after left ventricular assist device support.
    Schipper ME; Scheenstra MR; van Kuik J; van Wichen DF; van der Weide P; Dullens HF; Lahpor J; de Jonge N; De Weger RA
    J Heart Lung Transplant; 2011 Jul; 30(7):805-10. PubMed ID: 21531579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of Left Ventricular Assist Device Therapy on Cardiac Biomarkers: Implications for the Identification of Myocardial Recovery.
    Holzhauser L; Kim G; Sayer G; Uriel N
    Curr Heart Fail Rep; 2018 Aug; 15(4):250-259. PubMed ID: 29971612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal assessment of inflammation in recipients of continuous-flow left ventricular assist devices.
    Grosman-Rimon L; Jacobs I; Tumiati LC; McDonald MA; Bar-Ziv SP; Fuks A; Kawajiri H; Lazarte J; Ghashghai A; Shogilev DJ; Cherney DZ; Rao V
    Can J Cardiol; 2015 Mar; 31(3):348-56. PubMed ID: 25746024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction.
    Pascual-Figal DA; Ordoñez-Llanos J; Tornel PL; Vázquez R; Puig T; Valdés M; Cinca J; de Luna AB; Bayes-Genis A;
    J Am Coll Cardiol; 2009 Dec; 54(23):2174-9. PubMed ID: 19942089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction.
    AbouEzzeddine OF; McKie PM; Dunlay SM; Stevens SR; Felker GM; Borlaug BA; Chen HH; Tracy RP; Braunwald E; Redfield MM
    J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28214792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severity of oxidative stress and inflammatory activation in end-stage heart failure patients are unaltered after 1 month of left ventricular mechanical assistance.
    Caruso R; Verde A; Campolo J; Milazzo F; Russo C; Boroni C; Parolini M; Trunfio S; Paino R; Martinelli L; Frigerio M; Parodi O
    Cytokine; 2012 Jul; 59(1):138-44. PubMed ID: 22579113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sheet-Like Remodeling of the Transverse Tubular System in Human Heart Failure Impairs Excitation-Contraction Coupling and Functional Recovery by Mechanical Unloading.
    Seidel T; Navankasattusas S; Ahmad A; Diakos NA; Xu WD; Tristani-Firouzi M; Bonios MJ; Taleb I; Li DY; Selzman CH; Drakos SG; Sachse FB
    Circulation; 2017 Apr; 135(17):1632-1645. PubMed ID: 28073805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of pre-operative interleukin-6 levels with Interagency Registry for Mechanically Assisted Circulatory Support profiles and intensive care unit stay in left ventricular assist device patients.
    Caruso R; Verde A; Cabiati M; Milazzo F; Boroni C; Del Ry S; Parolini M; Vittori C; Paino R; Martinelli L; Giannessi D; Frigerio M; Parodi O
    J Heart Lung Transplant; 2012 Jun; 31(6):625-33. PubMed ID: 22386451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ST2 testing for chronic heart failure therapy monitoring: the International ST2 Consensus Panel.
    Januzzi JL; Pascual-Figal D; Daniels LB
    Am J Cardiol; 2015 Apr; 115(7 Suppl):70B-5B. PubMed ID: 25670638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and histopathological effects of heart failure drug therapy in advanced heart failure patients on chronic mechanical circulatory support.
    Catino AB; Ferrin P; Wever-Pinzon J; Horne BD; Wever-Pinzon O; Kfoury AG; McCreath L; Diakos NA; McKellar S; Koliopoulou A; Bonios MJ; Al-Sarie M; Taleb I; Dranow E; Fang JC; Drakos SG
    Eur J Heart Fail; 2018 Jan; 20(1):164-174. PubMed ID: 29094485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of multiple biomarkers in advanced stage heart failure patients treated with pulmonary artery catheter guided therapy.
    Zilinski JL; Shah RV; Gaggin HK; Gantzer ML; Wang TJ; Januzzi JL
    Crit Care; 2012 Jul; 16(4):R135. PubMed ID: 22830581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurohormonal regulation and improvement in blood glucose control: reduction of insulin requirement in patients with a nonpulsatile ventricular assist device.
    Koerner MM; El-Banayosy A; Eleuteri K; Kline C; Stephenson E; Pae W; Ghodsizad A
    Heart Surg Forum; 2014 Apr; 17(2):E98-102. PubMed ID: 24808450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of left ventricular assist device (HeartMate II): a Singapore experience.
    Lim CP; Sivathasan C; Tan TE; Lim CH; Kerk KL; Sim DK
    Artif Organs; 2014 Jul; 38(7):543-8. PubMed ID: 24392937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.